Screening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Nov 22

PMID 34804963

Citations 1

Authors

Yanting Shen

Huan Xu

Manmei Long

Miaomiao Guo

Peizhang Li

Ming Zhan

Zhong Wang

Affiliations

Soon will be listed here.

Abstract

Objectives: Existing prognostic risk assessment strategies for prostate cancer (PCa) remain unsatisfactory. Similar treatments for patients at the same disease stage can lead to different survival outcomes. Thus, we aimed to explore a novel immune landscape-based prognostic predictor and therapeutic target for PCa patients.

Methods: A total of 490 PCa patients from The Cancer Genome Atlas Project (TCGA) cohort were analyzed to obtain immune landscape-based prognostic features. Then, analyses at different levels were performed to explore the relevant survival mechanisms, prognostic predictors, and therapeutic targets. Finally, experimental verification was performed using a tissue microarray (TMA) from 310 PCa patients. Furthermore, a nomogram was constructed to provide a quantitative approach for predicting the prognosis of patients with PCa.

Results: The immune landscape-based risk score (ILBRS) was obtained. Then, VAV1, which presented a significant positive correlation with Treg infiltration and ILBRS, was screened and identified to be significantly related to the prognosis of PCa. Finally, experimental verification confirmed the prognostic value of VAV1 for PCa prognosis at the protein level.

Conclusions: VAV1 has the potential to be developed as an immune landscape-based PCa prognostic predictor and therapeutic target and will help improve prognosis by enabling the selection of individualized, targeted therapy.

Citing Articles

Methylation status of TK1 correlated with immune infiltrates in prostate cancer.

Zhang C, Ma S, Hao X, Wang Z, Sun Z Front Genet. 2022; 13:899384.

PMID: 36035114 PMC: 9403003. DOI: 10.3389/fgene.2022.899384.

References

Kang L, Hao X, Tang Y, Zhao Z, Zhang H, Gong Y . Elevated level of Vav1 was correlated with advanced biological behavior and poor prognosis in patients with gastric cancer. Int J Clin Exp Pathol. 2020; 11(1):391-398. PMC: 6957931. View

Huang R, Mao M, Lu Y, Yu Q, Liao L . A novel immune-related genes prognosis biomarker for melanoma: associated with tumor microenvironment. Aging (Albany NY). 2020; 12(8):6966-6980. PMC: 7202520. DOI: 10.18632/aging.103054. View

Jiang W, Guo Q, Wang C, Zhu Y . A nomogram based on 9-lncRNAs signature for improving prognostic prediction of clear cell renal cell carcinoma. Cancer Cell Int. 2019; 19:208. PMC: 6683339. DOI: 10.1186/s12935-019-0928-5. View

Liu Z, Zhong J, Cai C, Lu J, Wu W, Zeng G . Immune-related biomarker risk score predicts prognosis in prostate cancer. Aging (Albany NY). 2020; 12(22):22776-22793. PMC: 7746334. DOI: 10.18632/aging.103921. View

Scher H, Fizazi K, Saad F, Taplin M, Sternberg C, Miller K . Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367(13):1187-97. DOI: 10.1056/NEJMoa1207506. View

Cai W, Dong Z, Fu X, Lin L, Wang L, Ye G . Identification of a Tumor Microenvironment-relevant Gene set-based Prognostic Signature and Related Therapy Targets in Gastric Cancer. Theranostics. 2020; 10(19):8633-8647. PMC: 7392024. DOI: 10.7150/thno.47938. View

Carlsson S, Vickers A . Screening for Prostate Cancer. Med Clin North Am. 2020; 104(6):1051-1062. PMC: 8287565. DOI: 10.1016/j.mcna.2020.08.007. View

Rui X, Shao S, Wang L, Leng J . Identification of recurrence marker associated with immune infiltration in prostate cancer with radical resection and build prognostic nomogram. BMC Cancer. 2019; 19(1):1179. PMC: 6892211. DOI: 10.1186/s12885-019-6391-9. View

Patel P, Wessel T, Kawashima A, Okello J, Jamaspishvili T, Guerard K . A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer. Prostate. 2019; 79(14):1705-1714. DOI: 10.1002/pros.23895. View

10.

Van den Broeck T, van den Bergh R, Arfi N, Gross T, Moris L, Briers E . Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. 2018; 75(6):967-987. DOI: 10.1016/j.eururo.2018.10.011. View

11.

Proto J, Doran A, Gusarova G, Yurdagul Jr A, Sozen E, Subramanian M . Regulatory T Cells Promote Macrophage Efferocytosis during Inflammation Resolution. Immunity. 2018; 49(4):666-677.e6. PMC: 6192849. DOI: 10.1016/j.immuni.2018.07.015. View

12.

Intasqui P, Bertolla R, Sadi M . Prostate cancer proteomics: clinically useful protein biomarkers and future perspectives. Expert Rev Proteomics. 2017; 15(1):65-79. DOI: 10.1080/14789450.2018.1417846. View

13.

Shen Y, Xu L, Ning Z, Liu L, Lin J, Chen H . ARHGAP4 regulates the cell migration and invasion of pancreatic cancer by the HDAC2/β-catenin signaling pathway. Carcinogenesis. 2019; 40(11):1405-1414. DOI: 10.1093/carcin/bgz067. View

14.

Shao N, Tang H, Mi Y, Zhu Y, Wan F, Ye D . A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer. Oncoimmunology. 2020; 9(1):1762473. PMC: 7458664. DOI: 10.1080/2162402X.2020.1762473. View

15.

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

16.

Kruck S, Bedke J, Kuczyk M, Merseburger A . Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther. 2012; 12(6):777-85. DOI: 10.1586/era.12.43. View

17.

Hansen J, Bianchi M, Sun M, Rink M, Castiglione F, Abdollah F . Percentage of high-grade tumour volume does not meaningfully improve prediction of early biochemical recurrence after radical prostatectomy compared with Gleason score. BJU Int. 2013; 113(3):399-407. DOI: 10.1111/bju.12424. View

18.

Wu X, Lv D, Eftekhar M, Khan A, Cai C, Zhao Z . A new risk stratification system of prostate cancer to identify high-risk biochemical recurrence patients. Transl Androl Urol. 2021; 9(6):2572-2586. PMC: 7807327. DOI: 10.21037/tau-20-1019. View

19.

Strand S, Orntoft T, Sorensen K . Prognostic DNA methylation markers for prostate cancer. Int J Mol Sci. 2014; 15(9):16544-76. PMC: 4200823. DOI: 10.3390/ijms150916544. View

20.

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View